InnoCare and KeyMed license CD20xCD3 antibody ICP-B02 to Prolium for global development

TAGS

In a move poised to reshape the landscape of cancer and autoimmune treatments, and KeyMed Biosciences have signed an exclusive licensing agreement with for the development and commercialization of their cutting-edge bispecific antibody, (CM355). The deal grants Prolium the global rights to non-oncology applications and oncology indications outside of Asia, promising to expand access to transformative immunotherapy solutions worldwide.

What is ICP-B02 and How Does It Work?

ICP-B02 is a CD20xCD3 bispecific antibody designed to target CD20 proteins on tumor cells while simultaneously binding to CD3 proteins on T cells. This dual-target mechanism redirects and activates T cells, triggering T-cell Directed Cellular Cytotoxicity (TDCC) to eliminate tumor cells. The antibody’s innovative approach has demonstrated significant potential in oncology and non-oncology fields, offering hope for patients with complex medical conditions.

Ongoing Phase I/II clinical trials in China are evaluating ICP-B02’s safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with relapsed/refractory Non-Hodgkin lymphoma (NHL). Early results highlight the efficacy of both intravenous (IV) and subcutaneous (SC) formulations, particularly in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).

See also  Innovent Biologics showcases promising preclinical data at AACR 2024

Encouraged by these results, InnoCare and KeyMed are planning dose expansion studies combining ICP-B02 with other immunochemotherapies to target earlier treatment lines. The Investigational New Drug (IND) application for these combination therapies has already received regulatory approval, paving the way for broader clinical trials.

What Does the Licensing Agreement Include?

Under the terms of the agreement, Prolium Bioscience gains exclusive rights to:

  • Develop, manufacture, and commercialize ICP-B02 for non-oncology applications globally.
  • Handle oncology applications in regions outside of Asia.

In exchange, InnoCare and KeyMed will receive aggregate payments of up to $520 million, which include upfront fees, milestone payments, and tiered royalties on future sales. The agreement also grants the companies a minority equity stake in Prolium, strengthening their collaboration and ensuring long-term mutual benefit.

See also  KKR to acquire Japanese CDMO Bushu Pharmaceuticals from BPEA EQT

How Will This Partnership Advance Biopharma Innovation?

This collaboration highlights the growing importance of in addressing unmet medical needs. Prolium, a Delaware-based biopharma company funded by RTW Investments, LP, brings significant expertise in advancing disruptive technologies. Backed by a global investment firm focused on transformative innovations, Prolium is uniquely positioned to accelerate ICP-B02’s clinical and commercial development.

InnoCare and KeyMed, on the other hand, bring decades of experience in drug discovery and commercialization. KeyMed’s expertise lies in addressing urgent clinical needs through innovative yet affordable therapies, while InnoCare’s strong global presence and commitment to first- and best-in-class treatments ensure a steady pipeline of groundbreaking solutions.

What Does This Mean for Patients?

The agreement’s impact extends far beyond the business sphere, offering renewed hope to patients battling aggressive cancers and autoimmune conditions. By expanding ICP-B02’s applications globally, this collaboration could transform therapeutic outcomes for patients with limited treatment options.

See also  Keymed Biosciences secures NMPA approval for Stapokibart in chronic rhinosinusitis treatment

For NHL patients, ICP-B02 has already shown promise in improving survival rates. Its versatility in both standalone and combination treatments makes it a cornerstone of next-generation immunotherapies.

The Future of CD20xCD3 Bispecific Antibodies

The development of bispecific antibodies like ICP-B02 represents a significant leap forward in biopharmaceutical innovation. These therapies enable precision targeting of disease pathways, enhancing efficacy while minimizing side effects. With ICP-B02 at the forefront, the industry may witness a surge in similar therapies addressing complex diseases.

For InnoCare, KeyMed, and Prolium, the journey ahead will involve navigating regulatory hurdles, expanding clinical trials, and ensuring global patient access. The success of this partnership could redefine treatment standards across oncology and autoimmune specialties.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This